# Effect of SGLT2i on Diabetic Retinopathy in Type 2 Diabetes Mellitus Patients

> **NCT05310916** · PHASE3 · UNKNOWN · sponsor: **Nidae Alaa** · enrollment: 60 (estimated)

## Conditions studied

- Diabetic Retinopathy

## Interventions

- **DRUG:** Dapagliflozin 10mg Tab plus another oral hypoglycemic agent
- **DRUG:** Two oral hypoglycemic agents other than dapagliflozin

## Key facts

- **NCT ID:** NCT05310916
- **Lead sponsor:** Nidae Alaa
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-06
- **Primary completion:** 2023-05
- **Final completion:** 2023-11
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2022-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05310916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05310916, "Effect of SGLT2i on Diabetic Retinopathy in Type 2 Diabetes Mellitus Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05310916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*